The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.
Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.
After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.
Combining minoxidil, pyrilutamide, and copper peptide is questioned, with advice to apply them separately to avoid reactions. Finasteride and minoxidil are recommended for effectiveness.
The user is seeing progress in hair regrowth using a combination of 8% minoxidil, 0.25% dutasteride, and 0.01% tretinoin. The conversation includes comments on the effectiveness and application of these treatments.
Using a low dose of topical Tamoxifen effectively reduces gynecomastia caused by finasteride, with minimal side effects. The solution involves mixing Tamoxifen with ethanol and propylene glycol, applied daily to the chest.
The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
Using tretinoin or tazarotene with minoxidil may eliminate the need for microneedling or dermastamping. Microneedling can enhance minoxidil's effects but may cause long-term scalp issues.
The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.
Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.
Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.
The conversation discusses hair loss treatments, specifically progesterone therapy with hydrocortisone butyrate, and the use of dutasteride and finasteride. Opinions vary on the effectiveness and side effects of these treatments, with some users advocating for acceptance of balding if treatments are not suitable.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
User made progress with topical Finasteride/Minoxidil and topical Dutasteride for hair loss. Microneedling at 1.5mm daily was also mentioned as part of the treatment.
Hair mesotherapy with dutasteride is popular in Europe and can be effective, especially when combined with oral dutasteride. Some users suggest using topical dutasteride with microneedling as an alternative, though it may be painful.
The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
The user is using finasteride 1mg every other day and seeks a topical solution to complement it, excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.